Insights

Gathering insights about GOS…

Similar companies to GOS

GOS Tech Stack

GOS uses 8 technology products and services including AudioEye, AdRoll, Cloudflare, and more. Explore GOS's tech stack below.

AudioEye
Accessibility
AdRoll
Advertising
Cloudflare
Content Management System
Microsoft 365
Email
Twemoji
Font Scripts
reCAPTCHA
Security
Ninja Forms
Web Platform Extensions
FlexSlider
Widgets

Media & News

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer's Board of Directors approved the grant, effective November 5th, 2025, to six non-executive employees of non-qualified stock.
Nov 07, 2025 | www.businesswire.com
Gossamer Bio to Participate in Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the following investor conferences in November. UBS Global Healthcare Conference Date / Time: November 10th Format: 1x1's Location:.
Nov 07, 2025 | www.businesswire.com
Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates
Gossamer Bio (GOSS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.14 per share a year ago.
Nov 05, 2025 | www.zacks.com
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing seralutini.
Nov 05, 2025 | www.businesswire.com
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif. , Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has entered into an agreement with Gossamer Bio, Inc. (Gossamer) (Nasdaq: GOSS) granting Gossamer an option to acquire the Company.
Sep 25, 2025 | www.prnewswire.com
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acquire Respira Therapeutics (Respira) and its lead product candidate, RT234, an investigational inhaled vardenafil dry‑powder.
Sep 25, 2025 | www.businesswire.com
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025
SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralutinib will be presented at the European Respiratory Society (ERS) Congress 2025, which takes place from September 27th thro.
Sep 22, 2025 | www.businesswire.com

GOS's Email Address Formats

GOS uses at least 1 format(s):

GOS Email Formats	Example	Percentage
FLast@gos1.com	JDoe@gos1.com	49%
F.Last@gos1.com	J.Doe@gos1.com	1%
FLast@gos1.com	JDoe@gos1.com	49%
F.Last@gos1.com	J.Doe@gos1.com	1%

Frequently Asked Questions

Where is GOS's headquarters located?

GOS's main headquarters is located at 310 E. Frontage Road, Greer, South Carolina 29651, US. The company has employees across 5 continents, including North AmericaAsiaEurope.

What is GOS's phone number?

You can contact GOS's main corporate office by phone at

+1-800-277-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is GOS's stock symbol?

GOS is a publicly traded company; the company's stock symbol is GOSS.

What is GOS's official website and social media links?

GOS's official website is gos1.com and has social profiles on LinkedIn.

How much revenue does GOS generate?

As of October 2025, GOS's annual revenue is estimated to be $37M.

What is GOS's NAICS code?

GOS's NAICS code is 4532 - Office Supplies, Stationery, and Gift Stores.

How many employees does GOS have currently?

As of October 2025, GOS has approximately 149 employees across 5 continents, including North AmericaAsiaEurope. Key team members include Ceo: I. H.Chief Executive Officer: I. G.Vice President Of Sales: C. W. S.. Explore GOS's employee directory with LeadIQ.

What industry does GOS belong to?

GOS operates in the Retail Office Supplies and Gifts industry.

What technology does GOS use?

GOS's tech stack includes AudioEyeAdRollCloudflareMicrosoft 365TwemojireCAPTCHANinja FormsFlexSlider.

What is GOS's email format?

GOS's email format typically follows the pattern of FLast@gos1.com. Find more GOS email formats with LeadIQ.

When was GOS founded?

GOS was founded in 1968.

GOS

Q: What is GOS's official website and social media links?

GOS's official website is gos1.com. GOS has social profiles on LinkedIn.

Q: How many employees does GOS have currently?

GOS has approximately 149 employees.

Q: What technology does GOS use?

GOS's tech stack includes Ninja Forms, Nginx, Priority Hints, Google Cloud, JSON-LD.

Retail Office Supplies and GiftsUnited States51-200 Employees

Founded in 1968, GOS is one of the largest independently-owned office products companies in the United States. Greenville Office Supply is headquartered in SC and provides office products, toner and inkjet cartridges, workplace furniture, promotional products, coffee and beverage (break room) services, and janitorial and facility products. Nationwide next day free delivery for all products. For more information, visit www.gos1.com.

Company Overview

Headquarters: 310 E. Frontage Road, Greer, South Carolina 29651, US
Phone number: +1-800-277-****
Website: gos1.com
Stock Symbol: GOSS
NAICS Code: 4532 - Office Supplies, Stationery, and Gift Stores
Founded: 1968
Employees: 51-200

Media & News

Funding & Financials

$1B$10B
GOS's revenue is estimated to be in the range of $1B$10B

Funding & Financials

$1B$10B
GOS's revenue is estimated to be in the range of $1B$10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to GOS

HALO Branded Solutions

Proforma

AIA Corporation

GO2 Partners

4imprint

American Solutions for Business

A Brand Company

Cimpress

Axis Promotions

Staples Promotional Products

GOS Tech Stack

Media & News

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

GOS's Email Address Formats

Frequently Asked Questions

Where is GOS's headquarters located?

What is GOS's phone number?

What is GOS's stock symbol?

What is GOS's official website and social media links?

How much revenue does GOS generate?

What is GOS's NAICS code?

How many employees does GOS have currently?

What industry does GOS belong to?

What technology does GOS use?

What is GOS's email format?

When was GOS founded?

GOS

Company Overview

Media & News

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio (GOSS) Reports Q3 Loss, Tops Revenue Estimates

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?